Item 8.01 Other Events.
Press Release
On September 13, 2022, Recursion Pharmaceuticals, Inc. issued a press release
announcing the initiation of two clinical trials: TUPELO, its Phase 2 trial of
REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP);
and a Phase 1 trial for the potential treatment of Clostridium difficile (C.
diff) Colitis with Recursion's first new chemical entity to enter the clinic. A
copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release, dated September 13, 2022.
104 Cover Page Interactive Data File (formatted as Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses